Presenters and Affiliations:
- Mary Helen Witt, MD – Clinical Faculty, UVA Community Oncology
- Emily C. Ayers, MD, MSCE – Assistant Professor of Medicine, Division of Hematology/Oncology
- Craig A. Portell, MD – Associate Professor of Medicine, Division of Hematology/Oncology
Outline of Topics Presented:
- Introduction and Overview: The impact of CLL and therapeutic challenges.
- Case Studies and Treatment Strategies: Discussion of specific patient cases, their treatment history, and management strategies.
- COVID-19 and CLL Treatment: Addressing treatment choices in the era of COVID-19, including vaccine response and considerations.
- Mortality and Hospitalization Rates: Data on CLL patients’ outcomes during COVID-19.
- Minimal Residual Disease (MRD) Testing: Techniques and significance in treatment planning.
- BTK Inhibitors and Venetoclax: Discussion of their use, impact on MRD, and patient management.
- Clinical Decision Making: Approaches to treatment alterations based on MRD results and patient conditions.
- Future Directions in CLL Management: Insights into ongoing studies and evolving treatment strategies.
This educational video provides a comprehensive overview of the current landscape in CLL treatment, highlighting the challenges and advances in therapy, especially in the context of the COVID-19 pandemic. The presenters, all experts in the field of hematology and oncology, offer valuable insights into patient management, evolving treatments, and the importance of MRD in guiding therapy decisions.
Supported by
In partnership with
